Xultophy May Prove a Strong Growth Driver for NVO in 2018

Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017, a 252% YoY (year-over-year) rise on a reported basis and a 255% YoY rise in local currencies. The uptake of Xultophy, a combination of Tresiba and Victoza, was mainly driven by increasing demand in European and North American markets. Xultophy secured approval from the FDA on November 21, 2016, as a once-daily injectable adjunct therapy for type 2 diabetes patients who don’t respond adequately to a daily intake of 50 units of basal insulin or up to 1.8 mg of Victoza (liraglutide).